Severe hypocholesterolaemia is often neglected in haematological malignancies

European Journal of Cancer

Volumn 46, Issue 9, 2010, Pages 1735-1743

  Pugliese, Luca ^a   Bernardini, Ilaria ^b   Pacifico, Nazareno ^c   Peverini, Manola ^b   Damaskopoulou, Eleni ^b   Cataldi, Samuela ^b   Albi, Elisabetta ^b  

^a Polispecialistica Bios   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Ospedale Silvestrini   (Italy)

Author keywords

Cancer; Hypocholesterolaemia; Leukaemia; Lymphoma; Mevastatin

Indexed keywords

CHOLESTEROL; COMPACTIN; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER CELL; CELL GROWTH; CELL LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HYPOCHOLESTEROLEMIA; LYMPHOMA CELL; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; BLOOD; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTICHOLESTEREMIC AGENTS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL; FEMALE; HUMANS; LOVASTATIN; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; T-LYMPHOCYTES; YOUNG ADULT;

EID: 77952582310     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.03.041     Document Type: Article

References (45)

1. Jenkins D.J., Josse A.R., Wong J.M., Nguyen T.H., and Kendall C.W. The portfolio diet for cardiovascular risk reduction. Curr Atheroscler Rep 9 (2007) 501-507
2. Tatidis L., Vitols S., Gruber A., Paul C., and Axelson M. Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Lett 170 (2001) 169-175
3. Vitols S., Gahrton G., Björkholm M., and Peterson C. Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet 2 (1985) 1150-1154
4. Pugliese L., Bernardini I., Viola-Magni M.P., and Albi E. Low levels of serum cholesterol/phospholipids are associated with the antiphospholipid antibodies in monoclonal gammopathy. Int J Immunopathol Pharmacol 19 (2006) 331-337
5. Quesney-Huneeus V., Galick H.A., Siperstein M.D., et al. The dual role of mevalonate in the cell cycle. J Biol Chem 258 (1983) 378-385
6. Fairbanks K.P., Witte L.D., and Goodman D.S. Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem 259 (1984) 1546-1551
7. Myant N.B. The biology of cholesterol and related steroids (1981), Williams Heinemann Medical Book, London
8. Columbano A., Dessi S., Ledda-Columbano G.M., et al. HMP-shunt and cholesterol metabolism in experimental models involving normal and preneoplastic liver growth. Toxicol Pathol 15 (1987) 43-50
9. Wachtershauser A., Akoglu B., and Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22 (2001) 1061-1067
10. Danesh F.R., Sadeghi M.M., Amro N., et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA 99 (2002) 8301-8305
11. Alegret M., and Silvestre J.S. Pleiotropic effects of statins and related pharmacological experimental approaches. Meth Find Exp Clin Pharmacol 28 (2006) 627-656
12. Baba T.T., Nemoto T.K., Miyazaki T., and Oida S. Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway. J Muscle Res Cell Motil 29 (2008) 127-134
13. Pérez-Sala D., Gilbert B.A., Rando R.R., and Cañada F.J. Analogs of farnesylcysteine induce apoptosis in HL-60 cells. FEBS Lett 426 (1998) 319-324
14. García-Román N., Alvarez A.M., Toro M.J., Montes A., and Lorenzo M.J. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol Cell Neurosci 17 (2001) 329-341
15. Gauthaman K., Fong C.Y., and Bongso A. Statins, stem cells, and cancer. J Cell Biochem 106 (2009) 975-983
16. Weaver A.M. Invadopodia: specialized cell structures for cancer invasion. Clin Exp Metastasis 23 (2006) 97-105
17. Caldieri G., Giacchetti G., Beznoussenko G., et al. Invadopodia biogenesis is regulated by caveolin-mediated modulation of membrane cholesterol levels. J Cell Mol Med 13 (2009) 1728-1740
18. Di Vizio D., Solomon K.R., and Freeman M.R. Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori 94 (2008) 633-639
19. Rebillard A., Jouan-Lanhouet S., Jouan E., et al. Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. Eur J Cancer (2010) [Epub ahead of print]
20. Storch C.H., Ehehalt R., Haefeli W.E., and Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 323 (2007) 257-264
21. Montero J., Morales A., Llacuna L., et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res 68 (2008) 5246-5256
22. Bensinger S.J., Bradley M.N., Joseph S.B., et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134 (2008) 97-111
23. Shor R., Wainstein J., Oz D., et al. Low serum LDL cholesterol levels and the risk of fever, sepsis, and malignancy. Ann Clin Lab Sci 37 (2007) 343-348
24. Yavasoglu I., Tombuloglu M., Kadikoylu G., Donmez A., and Cagirgan S. Bolaman Z Cholesterol levels in patients with multiple myeloma. Ann Hematol 87 (2008) 223-228
25. Boyum A. Separation of lymphocytes, lymphocyte subgroups and monocytes: a review. Lymphology 10 (1977) 71-76
26. Rossi G., Magni M.V., and Albi E. Sphingomyelin-cholesterol and double stranded RNA relationship in the intranuclear complex. Arch Biochem Biophys 459 (2007) 27-32
27. Albi E., La Porta C.A.M., Castaldi S., and Viola Magni M. Nuclear sphingomyelin-synthase and protein kinase C delta in melanoma cells. Arch Biochem Biophys 438 (2005) 156-161
28. Albi E., Cataldi S., Bartoccini E., et al. Nuclear sphingomyelin pathway in serum deprivation-induced apoptosis of embryonic hippocampal cells. J Cell Physiol 206 (2006) 189-195
29. Weis M., Heeschen C., Glassford A.J., and Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 105 (2002) 739-745
30. Wang C.Y., Shui H.A., and Chang T.C. In vivo evidence of duality effects for lovastatin in a nude mouse cancer model. Int J Cancer 126 (2010) 578-582
31. Alvaro T., Lejeune M., García J.F., et al. Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells. Clin Cancer Res 14 (2008) 6856-6891
32. Chen R., Keating M.J., Gandhi V., and Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106 (2005) 2513-2519
33. Cecconi D., Zamò A., Bianchi E., et al. Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. Proteomic 8 (2008) 4495-4506
34. Jo S.H., Yang C., Miao Q., et al. Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities. J Immunol 177 (2006) 3737-3745
35. Garcia-Bates T.M., Peslak S.A., Baglole C.J., et al. Peroxisome proliferator-activated receptor gamma overexpression and knockdown: impact on human B cell lymphoma proliferation and serviva. Cancer Immunol Immunother 58 (2009) 1071-1083
36. Nakashima M., Cui Z.G., Tabuchi Y., et al. Apoptosis induced by an alkylated purine, 6-dimethylaminopurine, and changes in gene expression in human lymphoma U937 cells. Anticancer Res 28 (2008) 609-620
37. Theivagt A.E., Amanti E.N., Beresford N.J., Tabernero L., and Friesen J.A. Characterization of an HMG-CoA reductase from Listeria monocytogenes that exhibits dual coenzyme specificità. Biochemistry 45 (2006) 14397-14406
38. Banker D.E., Mayer S.J., Li H.Y., et al. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 104 (2004) 1816-1824
39. Cerda S.R., Wilkinson IV J., and Broitman S.A. Regulation of cholesterol synthesis in four colonic adenocarcinoma cell lines. Lipid 30 (1995) 1083-1092
40. Tam S.P., and Ramharack R. The effect of 25-hydroxycholesterol on the regulation of apolipoprotein E mRNA levels and secretion in the human hepatoma HepG2. Atherosclerosis 95 (1992) 137-146
41. Albi E., and Viola Magni M.P. Sphingomyelin: a small-big molecule in the nucleus. Recent Res Develop Biophys Biochem 37 (2006) 211-227
42. Yin Y., Russell R.G., Dettin L.E., et al. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 65 (2005) 3950-3957
43. Garcia-Bates T.M., Peslak S.A., Baglole C.J., et al. Peroxisome proliferator-activated receptor gamma overexpression and knockdown: impact on human B cell lymphoma proliferation and serviva. Cancer Immunol Immunother 58 (2009) 1071-1083
44. Edidin M. The state of lipid rafts: from model membrane to cells. Ann Rev Biophys Biomol Struct 32 (2003) 257-283
45. Gajate C., Gonzalez-Camacho F., and Mollinedo F. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One 4 (2009) e5044